A new report has found that emerging companies, most with no presence in Australia, are responsible for over 90 per cent of gene, cell and nucleotide therapies currently in late-stage pipelines. …
Latest Video
New Stories
-
The 'Dispatched' Week in Review Podcast - 1 May
May 1, 2026 - - Podcast -
UCB marks 25 years in Australia and advances national life science strategy
May 1, 2026 - - Latest News -
Stability now, change later? Fees unchanged while department undertakes charging model review
May 1, 2026 - - Latest News -
Bridge Program celebrates ten years of translating research into patient outcomes
May 1, 2026 - - Latest News -
New oral treatment offers more options for Australians with metastatic colorectal cancer
April 30, 2026 - - Latest News -
Moderna taps Salesforce to unify global commercial operations
April 30, 2026 - - Latest News -
How do we know the HTA institution loves patients? Because they use a love heart emoji
April 30, 2026 - - Latest News